Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224154 | 0.90 | MCL1 (0.31) | SRD5A2 | |
| SCHEMBL29224363 | 0.90 | MCL1 (0.31) | SRD5A2 | |
| SCHEMBL2098790 | 0.89 | SRD5A2 (0.34) | SRD5A2 | |
| SCHEMBL115766 | 0.85 | — | — | |
| SCHEMBL27460887 | 0.79 | SRD5A2 (0.33) | SRD5A2 | |
| SCHEMBL31203884 | 0.76 | — | — | |
| SCHEMBL24589163 | 0.76 | GPR119 (0.32) | — | |
| SCHEMBL428708 | 0.75 | — | — | |
| SCHEMBL31623264 | 0.75 | HSD11B1 (0.33) | — | |
| SCHEMBL16048822 | 0.74 | TP53 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125666-A1 | SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022026285-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1773338-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1773338-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618987-B2 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | SRD5A2 990/4885NR1H4 191/4885 |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | DNASE1, RNASEH1, RNASE1 | SRD5A2 3390/4885NR1H4 3215/4885 |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MC4R, MC5R, MC3R | SRD5A2 1598/4885NR1H4 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.